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Life is a combustion, but how the major fuel substrates that sustain human life compete and interact with each other for
combustion has been at the epicenter of research into the pathogenesis of insulin resistance ever since Randle proposed a
‘glucose–fatty acid cycle’ in 1963. Since then, several features of a mutual interaction that is characterized by both reciprocality
and dependency between glucose and lipid metabolism have been unravelled, namely:
(i) the inhibitory effects of elevated concentrations of fatty acids on glucose oxidation (via inactivation of mitochondrial
pyruvate dehydrogenase or via desensitization of insulin-mediated glucose transport),
(ii) the inhibitory effects of elevated concentrations of glucose on fatty acid oxidation (via malonyl-CoA regulation of fatty acid
entry into the mitochondria), and more recently
(iii) the stimulatory effects of elevated concentrations of glucose on de novo lipogenesis, that is, synthesis of lipids from glucose
(via SREBP1c regulation of glycolytic and lipogenic enzymes).
This paper first revisits the physiological significance of these mutual interactions between glucose and lipids in skeletal muscle
pertaining to both blood glucose and intramyocellular lipid homeostasis. It then concentrates upon emerging evidence, from
calorimetric studies investigating the direct effect of leptin on thermogenesis in intact skeletal muscle, of yet another feature of
the mutual interaction between glucose and lipid oxidation: that of substrate cycling between de novo lipogenesis and lipid
oxidation. It is proposed that this energy-dissipating substrate cycling that links glucose and lipid metabolism to thermogenesis
could function as a ‘fine-tuning’ mechanism that regulates intramyocellular lipid homeostasis, and hence contributes to the
protection of skeletal muscle against lipotoxicity.
doi:10.1038/sj.ijo.0802861
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Introduction
Obesity, type 2 diabetes and essential hypertensionFthree
major contributors to cardiovascular diseasesFshare many
epidemiological features. They have long been recognized to
be diseases of civilization with a very gradual onset, the
result of complex interplay between genetic susceptibility
and environmental factors, and with insulin resistance often
appearing as a relatively early development in all three
entities.1–3 What triggers the onset of insulin resistance (ie,
the decreased ability of peripheral target tissues to respond
properly to normal circulating concentrations of insulin) is
not clear. However, since during insulin stimulation the
skeletal muscle is the major site for glucose disposal,4 defects
in insulin-mediated glucose uptake and in its metabolic fate
in this tissue are thought to be early events in the
pathogenesis of insulin resistance.5,6 Indeed, muscle impair-
ments in insulin-mediated glucose transport, glycogen
synthesis and glucose oxidative pathways are the central
features of individuals at high risk for type 2 diabetes,
notably in the lean normoglycemic offspring of diabetic
patients and in obese patients.7,8 As these population groups
also present elevated plasma concentrations of fatty acids
and amino acids,9–11 these substrates or their metaboli-
tesFby interfering with the uptake and metabolism of
glucose in skeletal muscleFare thought to play a central role
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in the onset of insulin resistance.12 Furthermore, there is also
evidence that as chronic hyperglycemia develops, the over-
supply of glucose could also, by inhibiting fatty acid
oxidation, lead to the accumulation of intramyocellular
lipid metabolites that further inhibit glucose uptake/meta-
bolism and hence exacerbate the state of insulin resis-
tance.13–15
Since Randle’s proposal in 1963 of a glucose–fatty acid cycle
that embodies direct competition between substrates for
mitochondrial oxidation, a plethora of mechanisms have
been put forward to explain how fuel substrates could
interfere with glucose disposal in skeletal muscle.12,15
Particularly striking is that oversupply of each of the three
main fuel substrates canFas depicted in Figure 1Fconverge
towards the accumulation of triglycerides. This can occur
not only when the supply of circulating free fatty acid (FFA)
is in excess of its oxidation, but also when the supply of
amino acids or glucose exceeds the oxidation of these fuels,
thereby resulting in the formation of malonyl-CoA which,
by inhibiting carnitine palmitoyltransferase-1 (CPT-1), re-
duces the entry of long-chain fatty acyl-CoAs (FA-CoA) into
mitochondrial b-oxidation. The consequences of such lipid
overloading are the provision of lipid substrates (notably FA-
CoA, the product of triglyceride hydrolysis), which, if
unoxidized, could underscore the strong association be-
tween an elevated intramuscular lipid content and a variety
of ‘lipotoxic’ effects, namely:
(a) impairments in insulin signaling, in particular via
inhibition of phosphatidylinositol 3-kinase (PI3K) sig-
naling, a required step in insulin-stimulated glucose
transport into muscle, and/or
(b) ceramide synthesis and lipid peroxidation via nonox-
idative metabolic pathways, leading to cell dysfunction
and death through apoptosis.
Thus, the term ‘lipotoxicity’ encompasses toxicity that
may result not only from lipid overloading induced by excess
delivery vs oxidation of circulating FFA, but also from that
induced by glucose overloading (gluco-lipotoxicity) and
protein overloading (or proteo-lipotoxicity).
While these models of lipotoxicity explain how nutrient
supply exceeding oxidation may lead to insulin resistance in
skeletal muscle, a fundamental question that arises from a
perspective of integrative metabolic regulation is what
defense mechanisms may have evolved to enable fuel
oxidation to match an increase in fuel supply, and hence
contribute to blood glucose homeostasis and protection
against muscle lipotoxicity. In addressing this question, we
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Figure 1 Major pathways by which nutrients oversupply are thought to lead to insulin resistance and lipotoxicity in skeletal muscle: (a) surplus FFA, which is not
oxidized through the mitochondrial b-oxidation pathway, will lead to the enlargement of cytoplasmic pools of triglycerides (TG), diacylglycerols (DG) and long-
chain FA-CoA. The enlargement of these lipid pools, in particular DG and FA-CoA, could lead to a state of lipotoxicity in two main ways: (i) via activation of various
kinases (eg, protein kinase C isoforms, IkB kinase), which in turn lead to inhibition of IRSs associated with PI3K, a required step in insulin-stimulated glucose transport
into the muscle cells; and (ii) via ceramide synthesis and lipid peroxidation via nonoxidative metabolic pathways, leading to cell dysfunction and death through
apoptosis. (b) An oversupply of amino acids may also impair insulin-mediated glucose uptake by activating the mTOR/p70 S6 protein kinase pathway with
consequential inhibition of IRS-PI3K activity, whereas glucose oversupply can lead to inhibition of insulin-stimulated glucose uptake through the formation of
glucosamine. (c) Alternatively, surplus glucose or amino acids could also lead to increased conversion of acetyl-CoA to malonyl-CoA, under the catalytic action of
ACC. The generation of malonyl-CoA could, by inhibiting CPT-1, reduce mitochondrial fatty acid oxidation with consequential enlargement of the cytoplasmic pool
of FA-CoA and DG, thereby creating a state of gluco-lipotoxicity or proteo-lipotoxicity. (d) Absent from this illustration is the pathway through which malonyl-CoA
could also serve as a precursor for fatty acid synthesis in skeletal muscle because of the long-held assumption that de novo lipogenesis is practically absent in
myocytes. Emerging evidence, however, suggests that this pathway of de novo lipogenesis may have relevance for intramuscular lipid homeostasis, and this is a major
point for discussion later in the text. FA¼ fatty acids.
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first revisit the interactions between glucose and lipid
metabolism in skeletal muscle from a perspective of normal
physiology of blood glucose homeostasis, and subsequently
integrate novel facets of these interactions into a proposal for
a thermogenic mechanism of substrate cycling that could
offer protection against skeletal muscle lipotoxicity.
Interactions between glucose and lipids: from
Randle’s viewpoint
The notion that substrates compete for respiration has a long
history. It probably originates from the time of classic
calorimetric studies that were being conducted by Benedict
nearly 100 y ago,16,17 and gained credence in the 1930s
following the demonstration by Krebs18 of competition
between amino acids and glucose in kidney slices, followed
by that of Waters et al19 of competition between 3-
hydroxybutyrate and glucose in dog heart–lung prepara-
tions. But it was not until the early 1960s, following the
demonstration that lipid fuels inhibit glucose oxidation in
rat diaphragm and in perfused heart20,21 that Randle et al22,23
proposed a ‘glucose–fatty acid cycle’ as an important set of
mechanism by which carbohydrate and fat metabolism
interact. The essential components of this cycle have
recently been reiterated by Randle24 as follows:
(i) the relationship between glucose and fatty acid oxida-
tion is reciprocal and not dependent,
(ii) in vivo, the oxidation of lipid fuels (fatty acids and
ketone bodies) released into the circulation (eg, in
starvation or diabetes) may inhibit the catabolism of
glucose in muscle, and
(iii) in vitro, the oxidation of fatty acids released from muscle
triacylglycerol or intramyocellular triglycerides also
inhibit intracellular glucose metabolism.
In an elegant reappraisal of the glucose–fatty acid cycle
from a physiological perspective, Frayn25 points out that it is
appropriately called a ‘cycle’ because it describes a series of
events that interlink carbohydrate and fat metabolism. The
operation of this cycle in normal physiology would be as
follows:
(a) An elevated glucose concentration (typically in the post-
prandial state after a meal) stimulates insulin secretion,
which then suppresses FFA release from adipose tissue.
This removes competition for substrate utilization in
skeletal muscle, so that glucose utilization may be
stimulated by insulin, unimpeded by high concentra-
tions of fatty acids.
(b) Conversely, when plasma FFA concentrations are high,
usually it is because glucose and insulin concentrations
are low (typically in the post-absorptive state), fatty acids
then naturally become the major fuel for skeletal muscle.
To quote Frayn:25 ‘This makes perfect physiological sense
in terms of blood glucose homeostasis. The ‘coarse’ control
of the reciprocal utilization of glucose and FFA in the body is
brought about through insulin secretion: fine-tuning is
provided in skeletal muscle’.
Glucose–fatty acid interactions in skeletal muscle:
from reciprocality to dependency
During the past 40 y, since the glucose–fatty acid cycle was
first proposed,22 several major facets of the complex inter-
relationship between glucose and lipid metabolism have
been unraveled in skeletal muscle. As discussed below, they
constitute various sets of mechanisms that underscore not
only reciprocal relationships between glucose and lipid
metabolism but also relationships that show dependency
between these two major oxidative fuel substrates for
mammalian metabolism.
Inhibitory effects of lipids on glucose metabolism
The inhibitory effects of elevated concentrations of lipid
fuels (fatty acids and ketone bodies) on glucose disposal and
glucose oxidation in skeletal muscle have been firmly
established by numerous studies conducted both in vivo
and in vitro.24,25 In particular, it has been demonstrated in
humans that under in vivo conditions when fatty acid
concentrations are elevated (eg, in response to infusion of
lipid emulsions together with heparin) whole body and
skeletal muscle glucose utilizations are impaired.26–28 The
mechanisms put forward to explain how fatty acids limit
insulin-stimulated glucose utilization fall into two main
categories, both of which were first proposed by Randle
following the original studies which formed the basis of the
glucose–fatty acid cycle,20–23 namely: (a) via fatty acid-
induced desensitization of insulin-mediated glucose trans-
port and (b) via inhibitory effects of fatty acid oxidation.
According to the Randle hypothesis for the latter mechan-
ism,22,24 an increase in lipid oxidation in muscle will
decrease glucose oxidation by suppression of the mitochon-
drial pyruvate dehydrogenase complex, with the consequen-
tial reduction of glycolytic flux resulting in an increase in
glucose-6-phosphate, inhibition of hexokinase activity, and
ultimately leading to decreased glucose uptake. Nonoxida-
tive metabolism (storage) of glucose is also, therefore,
predicted to be decreased. A variety of model systems have
largely confirmed the validity of this Randle’s mechanism, at
least in terms of the acute effects of fatty acids on muscle
glucose metabolism and storage.24,29
Since the mid-1990s, however, the mechanisms by which
fatty acids may desensitize insulin-mediated glucose trans-
port have received much more attention. According to
models that have substantial in vivo and in vitro experimental
support, fatty acids or more specifically their metabolites
(fatty acyl CoAs, diacyglycerols or even ketone bodies)
decrease insulin sensitivity by activation of serine kinase
cascades, leading to decreased insulin receptor substrate
3
(IRS)-1 tyrosine phosphorylation and decreased IRS-1-asso-
ciated PI3K activity.6,12,30 Other proposed mechanisms have
implicated the inhibitory effects of fatty acids (or their
metabolites) directly on GLUT4, the major insulin-stimu-
lated glucose transporter.31 Taken together, there is still
uncertainty regarding which specific metabolites and reg-
ulatory pathways are directly responsible for insulin desen-
sitization in response to fatty acids, but the suppressive
effects of elevated concentrations of lipids on glucose
oxidation in skeletal muscle is unequivocal.
Inhibitory effects of glucose on lipid oxidation
A turning point in elucidating the reciprocal nature of
interactions between glucose and lipid metabolism occurred
in the late 1970s following the demonstration of McGarry
et al32,33 that high glucose (and insulin) concentrations can
suppress hepatic fatty acid oxidation through malonyl-CoA
inhibition of CPT-1, a key rate-limiting enzyme that controls
the entry of fatty acids into the mitochondrial b-oxidation
system. As this mechanism by which glucose might regulate
fatty acid oxidation is an almost exact complement to the
mechanism described by Randle and colleagues, it is often
referred to as the ‘reverse glucose–fatty acid cycle’. Malonyl-
CoA inhibition of fatty acid oxidation may be expected to
contribute to the switch to pyruvate oxidation, and
conversely, inhibition of acetyl-CoA carboxylase (ACC),
which is required to produce malonyl-CoA from acetyl-
CoA, might be expected to facilitate fatty acid oxidation at
the expense of glucose oxidation. This reverse glucose–fatty
acid cycle can be viewed as further ‘fine-tuning’ of the
balance between glucose and fatty acid metabolism. The
question arose nonetheless as how to reconcile the inhibi-
tion of mitochondrial fatty acid oxidation by an elevation in
malonyl-CoA when this intermediate substrate (that is
formed from acetyl-CoA under the catalytic action of ACC)
is also an immediate precursor for de novo synthesis of fatty
acids.34 Such a role for malonyl-CoA both as a precursor of
lipid synthesis and an inhibitor of lipid oxidation was
subsequently reconciled with the discovery that there are
in fact two isoforms of ACC:35,36 ACC-1 expressed predomi-
nantly in ‘lipogenic’ tissues that synthesize large amounts of
fatty acids (liver, adipose tissue) and ACC-2 expressed in
‘nonlipogenic’ tissues such as skeletal muscle and cardiac
muscle. More recent advances in the mechanism by which
malonyl-CoA is regulated by ACC point to the subcellular
localization of the ACC isoforms and to the compartmenta-
lization of malonyl-CoA in the cell.37 ACC-1 is thought to
reside in the cytoplasm, where it synthesizes the pool of
malonyl-CoA that is used for de novo lipogenesis, whereas
ACC-2, by contrast, is thought to control the pool of
malonyl-CoA that regulates fatty acid oxidation. This iso-
form-specific role results from its postulated capacity to
associate with mitochondria, which juxtaposes the ACC-2
enzyme with mitochondrial CPT-1.38
In skeletal muscle, the suppressive effect of an elevated
concentration of glucose on fatty acid oxidation is now
recognized to occur via malonyl-CoA-sensitive CPT-1 (mal-
onyl-CoA being synthesized by ACC-2), but the question of
whether a cytoplasmic pool of malonyl-CoA might be
utilized for fatty acid synthesis has rarely been invokedF
most probably because of the long-held assumption that
skeletal muscle is not an organ where de novo lipogenesis
occurs. Indeed, whenever the expression or activity of a key
rate-limiting enzyme for de novo lipogenesis (eg, fatty acid
synthase which catalyzes the conversion of malonyl-CoA to
fatty acids) was reported in skeletal muscle, this was
attributed to artifactual contamination from adipocyte
infiltration rather than to de novo lipogenesis occurring in
myocytes.39,40 Consequently, the importance of skeletal
muscle substrate metabolism in the homeostatic control of
blood glucose has been viewed entirely from the reciprocal
nature of interactions between glucose and lipid metabo-
lism. Recent evidence, however, suggests otherwise. As
discussed below, de novo lipogenesis can indeed be shown
to occur in muscle cells and to be modulated by factors
influencing nutritional status, thereby revealing another
facet of interactions between glucose and lipid metabolism
that shows dependency between these two fuel substrates in
skeletal muscle.
Stimulatory effects of glucose on muscle de novo
lipogenesis
The recent recognition that de novo lipogenesis might have
relevance for lipid homeostasis in skeletal muscle stems from
the realization that Sterol regulatory element binding
protein-1c (SREBP-1c), a member of the family of transcrip-
tion factors that regulate the expression of genes involved in
lipid storage in liver and adipose tissue, is also present in
skeletal muscle at a level close to that observed in the
liver,41,42 and that its dysregulation might lead to increased
lipid storage, and hence contribute to the pathogenesis of
insulin resistance. There is now evidence both in humans
and in rodents that SREBP-1c mediates insulin upregulation
of genes encoding glycolytic and lipogenic enzymes in
skeletal muscle,42–46 but most fascinating are the very recent
demonstrations that glucose alone (in the absence of insulin)
can stimulate de novo lipogenesis in skeletal muscle cells. The
evidence can be summarized as follows:
(i) Using contracting myotubes derived from rat muscle
satellite cells, Guillet-Deniau et al47 demonstrated that
glucose alone stimulates, more rapidly than insulin, the
expression of hexokinase II, fatty acid synthase and
ACC-2 proteins, leading to an increased lipogenic flux
and intracellular lipid accumulation in these cultured
muscle cells. Furthermore, the knockdown of SREBP-1
mRNAs (using an RNA-interference technique) demon-
strated that this transcription factor directly mediated
the glucose upregulation of lipogenic enzymes in
skeletal muscle.
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(ii) In another recent study by Aas et al48 to evaluate the
potential effects of hyperglycemia on glucose and lipid
metabolism in human muscle cells, it was shown that
glucose oversupply leads to increased triglyceride accu-
mulation and the incorporation of glucose into tri-
glycerides, concomitantly with a reduced insulin-
stimulated glucose uptake and glycogen synthesis,
without alterations in fatty acid oxidation. In other
words, the increased intramyocellular lipid storage did
not result from decreased fatty acid oxidation but from
de novo lipogenesis.
Again here, the fact that the formation of malonyl-CoA for
de novo synthesis of fatty acids did not result in inhibition of
fatty acid oxidation suggests that either (a) the increase in
malonyl-CoA may not have exceeded the threshold required
for inhibition of CPT-1, or that (b) the malonyl-CoA directed
at the synthesis of lipids may have derived essentially from
the cytosolic pool synthesized by ACC-1 rather than from
the pool localized near to the mitochondria (and synthesized
by ACC-2) that are involved in the regulation of fatty acid
oxidation. Whatever the explanation, it is clear that de novo
lipogenesis, although low in skeletal muscle, can be
markedly stimulated in muscle cells, particularly under
conditions of high glucose (and/or high insulin) concentra-
tions. These findings in primary muscle cell cultures are
consistent with recent data from our laboratory, which
demonstrate that de novo lipogenesis can also occur in intact
skeletal muscle. As shown in Figure 2, incubation of intact
mouse muscle preparations in buffer containing 14C-labeled
glucose resulted in the production of 14C-labeled lipids
corresponding to FFAs, diglycerides and triglycerides when
analyzed by thin-layer chromatography, and that insulin
increased the synthesis of lipids from glucose in the soleus
muscle (predominantly oxidative fibre type), and to a lesser
extent in the extensor digitorium longus (EDL) muscle
(predominantly glycolytic fibre type). This experiment
demonstrates that de novo lipogenesis can occur in skeletal
muscle independently of muscle type and that it can be
stimulated by insulin as in the liver and adipose tissue.
What could then be the normal physiological significance
of de novo lipogenesis in skeletal muscle? Extrapolated to
conditions of postprandial elevation in blood glucose and
insulin (particularly after a high-carbohydrate meal), de novo
lipogenesis in skeletal muscle, like in the liver, could also
contribute to blood glucose homeostasis by disposing some
of the excess circulating glucose as muscle triglycerides,
particularly if the glycogen stores are full. In other words, de
novo lipogenesis in myocytes may provide another sink for
glucose disposal through skeletal muscle. However, given the
well-established connection between an elevated intramyo-
cellular lipid and insulin resistance, the concept of an
increase in de novo lipogenesis in skeletal muscle as an
‘adaptive’ physiological reaction to post-prandial hypergly-
cemia is only tenable if the lipids synthesized de novo were to
be subsequently oxidizedFthat is, through an increase in
muscle thermogenesis. Two separate lines of investigations
converge to support this contention. First, a link between
glucose disposal and a disproportionate increase in skeletal
muscle thermogenesis (unaccounted for by the energy costs
for glucose uptake and storage as glycogen) has indeed been
demonstrated in humans during measurements of forearm
O2 consumption for several hours after an oral glucose
load.49 Second, as discussed below, recent work from our
laboratory investigating the mechanisms by which leptin-
Fanother hormone whose blood concentrations rise during
the post-prandial state50,51Fmay interact with insulin to
stimulate thermogenesis in skeletal muscle, suggests the
possible existence of a thermogenic pathway of substrate
cycling in which lipids derived from glucose (ie, by de novo
lipogenesis) are subsequently oxidized.
Substrate cycling between de novo lipogenesis and lipid
oxidation
It is now well established that the adipocyte-derived
hormone leptin, which is well known for its central role in
body weight regulation in part via its control over thermo-
genesis,52–55 also plays an important role in blood glucose
homeostasis and in the protection of insulin-sensitive tissues
against excessive ectopic lipid storage by regulating the
partitioning of fatty acid away from storage towards oxida-
tion.56–58 As depicted in Figure 3, the earlier demonstrations
that leptin can act directly on skeletal muscle, specifically via
the long form of the leptin receptor (ObRb), to stimulate
glucose utilization in a PI3K-dependent manner59,60 and
lipid oxidation via the activation of AMP-activated protein
1 2 3 4
Palmitate
TG
MG
1,2 DG 
1,3 DG
5 6 7 8
EDL
Insulin - + - +
Soleus
Figure 2 De novo lipogenesis in intact skeletal muscle. Phosphor imaging of
thin layer chromatography showing conversion of D-[14C]-glucose into [14C]-
lipids in mouse soleus and EDL, predominantly oxidative and glycolytic
muscles, respectively, incubated in Krebs–Ringer buffer containing 5mM
glucose supplemented with D-[14C]-glucose: lanes 3 and 5 contain lipids
extracted from muscles incubated in control buffer, and lanes 4 and 6 contain
lipids extracted from muscles incubated with 100nM insulin; lipid standards
are as follows: lane 1 and 8, 14C-labeled palmitate; lanes 2 and 7, mixture of
unlabeled mono- (MG), di- (DG) and tri-glycerides (TG) that were detected
colorimetrically. For details of incubation and analysis, see Solinas et al.63
5
kinase (AMPK) leading to inhibition of ACCs58,61 prompted
us to investigate whether leptin could also exert direct
control on thermogenesis in skeletal muscle. Using a method
that involves repeated measurements of O2 consumption in
intact muscle perifused ex vivo with Krebs–Ringer buffer, we
found that leptin could directly stimulate thermogenesis in
skeletal muscle via ObRb,62 and that this thermogenic effect
of leptin, which requires PI3K activity (since it is inhibited by
wortmannin), is potentiated by insulin, a potent activator of
PI3K. A requirement for AMPK activation and for entry of
fatty acids through the mitochondrial b-oxidation pathway
was also suggested by the fact that leptin-induced thermo-
genesis was inhibited either in the presence of araA (an
inhibitor of AMPK) or by addition of etomoxir, an inhibitor
of CPT-1.63 In other experiments that involved interference
with key control points of intermediary metabolism in order
to investigate the nature of an ‘apparent’ link between
leptin’s direct effects on skeletal muscle to stimulate glucose
metabolism,58–60 lipid oxidation57–61 and thermogenesis,62
evidence emerged of a requirement for de novo lipogenesis in
the mechanism by which leptin stimulates muscle thermo-
genesis.63 Specifically, the direct thermogenic effect of leptin
on skeletal muscle O2 consumption was found to be
completely inhibited by the addition of any one of the
following compounds that would inhibit the synthesis of
lipids from glucose, namely (a) 2-deoxyglucose, which
interferes with glucose metabolism, (b) hydroxy-citrate,
which inhibits citrate lyase and hence the conversion of
citrate to acetyl-CoA and (c) cerulenin, which inhibits fatty
acid synthase and hence the conversion of malonyl-CoA to
fatty acids. Taken together, these studies suggest that the
direct effect of leptin in stimulating thermogenesis in
skeletal muscle could be mediated by substrate cycling
between de novo lipogenesis and lipid oxidation, and that
the orchestration of this substrate cycling requires both PI3K
and AMPK signaling.
It is proposed that in this substrate cycle (depicted in
Figure 3), which underscores the interdependency between
glucose, lipids and thermogenesis, acetyl-CoA produced
from glucose and fatty acid oxidation will overload the
Krebs cycle. This will result in excess mitochondrial citrate,
which, in the cytoplasm, will exert an allosteric activation of
ACCs and, at the same time, under the action of citrate lyase,
will provide acetyl-CoA to ACCs for the synthesis of
malonyl-CoA. The latter will serve as the main substrate for
fatty acid synthase, thereby producing a new pool of fatty
acids. Glucose plays a central role in this cycle as a source of
acetyl-CoA, Krebs cycle intermediates and NADPH mole-
cules, which are required for the synthesis of FAs. It might
also function as a stimulator of de novo lipogenesis, based
upon the above-mentioned recent demonstrations in muscle
satellite cells47,48 that glucose, even in the absence of insulin,
stimulates the gene expression of SREBP-1c as well as key
genes encoding glycolytic and lipogenic enzymes, leading to
an increased lipogenic flux.
It is postulated that PI3K and AMPK signaling could
orchestrate this futile cycle between de novo fatty acid
synthesis and fatty acid oxidation. On the one hand,
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Figure 3 Biochemical model integrating an energy-dissipating substrate cyling between de novo lipogenesis and lipid oxidation (orchestrated by PI3K and AMPK
signaling) in skeletal muscle. The possible existence of this substrate cycling rests upon data from calorimetric studies showing that the direct effect of leptin on
skeletal muscle thermogenesis is potentiated by insulin and inhibited by pharmacological interference at any one of the key control points in the flux of substrates
denoted by symbol (X), namely: (i) with glucose metabolism using 2-deoxyglucose, (ii) with the conversion of citrate to acetyl-CoA using hydroxy-citrate, an
inhibitor of citrate lyase, (iii) with the conversion of malonyl-CoA to fatty acids using cerulenin, an inhibitor of fatty acid synthase and (iv) with the entry of fatty acid
into mitochondrial b-oxidation pathway using etomoxir, an inhibitor of CPT-1. It is postulated that other hormones (eg, catecholamines, adiponectin), which have
been shown to activate AMPK signaling in skeletal muscle, could also interact with insulin to influence the rate of this thermogenic substrate cycling, and hence play
a role in intramuscular lipid homeostasis. See text for details. FA¼ fatty acids; TG¼ triglycerides.
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activation of AMPK, by phosphorylating ACCs, will counter-
balance the stimulatory action of citrate on ACCs to result in
reduced malonyl-CoA concentration, disinhibition of CPT-1
and increased fatty acid oxidation, which in turn will lead to
the production of acetyl-CoA and consequently overloading
of the Krebs cycle. On the other hand, PI3K activity (basal or
insulin-stimulated) will increase glucose entry and allow the
excess citrate to enter pathways leading to the synthesis of
fatty acids. This would occur despite AMPK-induced reduc-
tion in malonyl-CoA since it is known that full phosphor-
ylation of ACCs by AMPK results in an inhibition of ACC
activities only by 50–60%.64,65 Such partial inhibition of
ACCs is expected to redirect the flux of acetyl-CoA and
malonyl-CoA towards fatty acid oxidation, but would still
allow substantial rate of fatty acid synthesis, particularly in
the presence of high levels of citrate. Alternatively, the
insulin–leptin interactions in skeletal muscle may orches-
trate the regulation of distinct intracellular pools of malonyl-
CoA via maintenance of the ACC-1-generated ‘lipogenic’
pool (through PI3 kinase signaling) and diminution of the
ACC-2-generated ‘CPT-1-sensitive’ pool (via AMPK signal-
ing). One can also entertain the interesting possibility that,
in skeletal muscle, this substrate cycling is also activated in
response to other hormones and neurotransmitters (eg,
adiponectin, catecholamines) particularly since adiponectin,
as well as adrenergic agonists, can also stimulate AMPK
activity, glucose utilization and fatty acid oxidation in
skeletal muscle or adipose tissue.61,66–69 This substrate
cycling between de novo lipogenesis and lipid oxidation
could therefore constitute a thermogenic effector in skeletal
muscle. Theoretically, the synthesis of one molecule of
palmitic acid from acetyl-CoA and its re-oxidation to acetyl-
CoA would cost at least 14 molecules of ATP. Repeated
recycling of acetyl-CoA through the flux of substrates across
lipogenesis, followed by lipid oxidation, could therefore
constitute an important thermogenic pathway that provides
a sink not only for intramuscular glucose disposal, but also
for dissipating excess lipids.
The existence of this futile cycle in skeletal muscle
provides a mechanistic link between glucose utilization,
fatty acid metabolism and thermogenesis, analogous to the
relation between substrate metabolism and thermogenesis in
brown adipose tissue. In this tissue, whose primary function
is to produce heat for thermoregulation in human newborns
and small mammals, it has long been known that much of
the fuel for thermogenesis also derives from glucose being
first converted to lipids before being oxidized.70–73 More
direct evidence that de novo lipogenesis is in fact critical for
brown adipose tissue thermogenesis can be derived from
recent studies in cold-exposed mice indicating that pharma-
cological suppression of de novo lipogenesis leads to marked
reductions in brown adipose tissue thermal response to
noradrenaline infusion (despite normal UCP1 levels) and
resulted in the development of hypothermia.74 One can
therefore also refer to thermogenesis in brown adipose tissue
as dependent upon substrate cycling between de novo
lipogenesis and lipid oxidation, but whose rate is greatly
amplified under sympathetic activation of mitochondrial
proton leak in this tissue.
Interdependency between glucose, lipids and
thermogenesis
Thus, although research towards understanding how the
major oxidative fuels interact for combustion in skeletal
muscle has been dominated by concepts of reciprocal
interactions between glucose and lipid oxidation, the notion
of interdependency between glucose uptake/metabolism, lipid
oxidation and thermogenesis is not entirely new. It has been
discussed by Masaro in the early 1960s in the context of a
role for adipose tissue metabolism in nonshivering thermo-
genesis pertaining to body temperature regulation.70
Furthermore, this ‘dependency’ interaction between these
two substrates and thermogenesis is well recognized at the
whole-body level, and is attributed to activation of a neuro-
endocrine network (comprising insulin, leptin and the sym-
pathoadrenal system), which plays a pivotal role in several
overlapping regulatory systems: that of blood glucose, body
temperature, body weight and more recently intramyocel-
lular lipids.56–58 Interference with any of these hormones or
their actions leads to major impairments in all these
overlapping regulatory functions. In particular, the absence
of functional leptin (eg, in the ob/obmouse) or dysfunctional
leptin signaling (eg, in db/dbmice or fa/fa rats) leads not only
to impairments in thermogenesis that contribute to obesity,
but also to hyperglycemia and excessive accumulation of
lipids in nonadipose tissues, including the skeletal muscle.56–58
The fact that, in these animal models, the stimulation of
thermogenesis induced by leptin replacement58 or by
treatment with b3 adrenoceptor agonists75 improves insulin
sensitivity and reduces ectopic fat storage at low-dose levels
or over time periods that do not affect body weight strongly
suggests that impaired thermogenesis might be an early
event in the dysregulation of blood glucose and intramyo-
cellular lipids. To date, however, the molecular mechanisms
underlying thermogenesis in tissues other than the brown
adipose tissue remains elusive, amid continuing controver-
sies concerning the physiological roles of UCP2 and UCP3
(homologs of UCP1) as effectors of skeletal muscle thermo-
genesis.76,77 The energy-dissipating substrate cycle that links
glucose and lipid metabolism to thermogenesis in skeletal
muscle (depicted in Figure 3) provides a novel molecular
mechanism of thermogenesis through which this above-
mentioned neuroendocrine networkFoperating through
insulin, leptin and catecholaminesFoverlaps in the regula-
tion of body weight, blood glucose and intramyocellular
lipids, and hence in the protection against obesity, hyper-
glycemia and lipotoxicity. Perturbations in this neuro-
endocrine network (and intracellular signaling system) that
exerts control over this substrate cycling may thus be early
events that lead to intramyocellular lipid accumulation, and
7
hence to the consequential effects of this state of lipotoxicity
on the onset and exacerbation of insulin resistance.
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